Emcure Pharma IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Emcure Pharma

CMP

1,283.15

-40.30 (-3.05%)

  • DRHP
₹1,008

Offer Price

₹ 1,952.03 Cr

Issue Size

₹ 14,112

Min Investment

67.87x

Times Subscribed

14

Lot size

Time Line

  • 03
    Jul 2024
    Open
  • 05
    Jul 2024
    Close
  • 08
    Jul 2024
    Finalisation of Basis of Allotment
  • 09
    Jul 2024
    Initiation of Refunds
  • 09
    Jul 2024
    Transfer of Shares to Demat Account
  • 10
    Jul 2024
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Increase its Market Share in the Domestic Market.

  • Continue to Invest in Research & Development and Manufacturing Capabilities to Enhance and Grow our Differentiated Product Portfolio.

  • Deepen and Expand its International Presence with a Focused Go-to-Market Approach.

  • Pursue Strategic Acquisitions, Partnerships and In-Licensing Arrangements.

Products & Services

  • Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Strengths

  • Well-placed to leverage leading position in the domestic market.

  • Demonstrated capabilities of building brands.

  • Large, diversified and fast-growing product portfolio in international markets.

  • Strong R&D capabilities driving differentiated portfolio of products.

  • Extensive and diversified manufacturing capacity.

Risks

  • Any manufacturing or quality control problems may damage its reputation, subject it to regulatory action, and expose it to litigation or other liabilities, which could adversely affect the company reputation, business, financial condition and results of operations.

  • Its failures to comply with applicable quality standards may result in product liability claims, which could adversely affect its business, financial condition, cash flows and results of operations.

  • Its manufacturing and research and development operations are subject to operational risks. Any slowdown or shutdown in its manufacturing or research and development operations could adversely affect its business, financial condition and results of operations.

  • The company is subject to extensive government regulations and if its fail to obtain, maintain or renew the company statutory and regulatory licenses, permits and approvals required to operate its business, the company`s business, financial condition, results of operations and cash flows may be adversely affected.

  • Any disruptions to the supply, or increases in the pricing, of the raw materials and finished products that its outsource, may adversely affect the supply and pricing of its products and, in turn, adversely affect the company`s business, cash flows, financial condition and results of operations.

Company Promoters

Promoters Holding

Issue For IPO
54.42%
Pre Holding

54.42%

Post Holding

-

Top Promoters Holding

Financials

All values in Cr

Mar-2023 Mar-2024 Mar-2023 3-Yr trend
Revenue 5,985.81 (2.20%) 6,658.25 (11.20%) 16.87 (-)
Gross Profit 5,985.81 (2.20%) 6,658.25 (11.20%) 16.87 (-)
Net Income 5,985.81 (2.20%) 6,658.25 (11.20%) 16.87 (-)
Assets 5,985.81 (2.20%) 6,658.25 (11.20%) 16.87 (-)
Liabilities 5,985.81 (2.20%) 6,658.25 (11.20%) 16.87 (-)

Peers

Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Emcure Pharmaceuticals Ltd 5,985.81 532.02 5,089.43 2,588.31 16.87 29.42 138.30 2.41 0.46
Dr Reddy`s Laboratories Ltd 24,669.70 4,507.30 32,285.10 32,285.10 19.35 271.47 1,397.72 13.96 0.05
Cipla Ltd 22,753.12 2,801.91 29,463.28 29,463.28 11.96 34.69 293.79 9.50 0.02
Alkem Laboratories Ltd 11,599.26 984.17 13,756.65 13,756.65 10.88 82.31 789.21 7.15 0.14
Torrent Pharmaceuticals Ltd 9,620.15 1,245.23 15,011.85 15,011.85 20.09 36.79 183.13 8.29 0.85
Mankind Pharma Ltd 8,749.43 1,281.86 9,715.45 9,715.45 17.24 32.00 190.30 13.19 0.02
Abbott India Ltd 5,348.73 949.41 4,555.51 4,555.51 29.77 446.78 1,500.49 20.84 0.00
J B Chemicals & Pharmaceuticals Ltd 3,149.28 409.84 3,553.87 3,553.87 16.52 53.00 320.55 11.53 0.22

Book Running Managers

  • Axis Capital Ltd
  • Kotak Mahindra Capital Company Ltd
  • Jefferies India Pvt Ltd
  • J.P. Morgan India Pvt Ltd

Registrar & Transfer Agent

Link Intime India Pvt Ltd

C-101 247 Park,
L B S Marg,
Vikhroli West - Mumbai-400083
Phone : 91-22-49186000 Fax: 91-22-49186060

Company Contact Information

Plot # P-1 & P-2 IT BT Park,
Phase II MIDC Hinjawadi,
Pune - 411057
Phone : +91 20 3507 0033/+91 20 3507 0000 Email : investors@emcure.com www.emcure.com

Offer Related Information

Initial public offering of 19,375,070 equity shares of face value of Rs. 10 each ("Equity Shares") of Emcure Pharmaceuticals Limited (The "Company") for cash at a price of Rs. 1,008^ per equity share (including a share premium of Rs. 998 per equity share) (the "Offer Price") aggregating to Rs. 1952.03^ crores (the "Offer") comprising a fresh issue of 7,946,231 equity shares of face value of Rs. 10 each aggregating to Rs. 800.00^ crores by the company (the "Fresh Issue") and an offer for sale of... More

News

  • No Data Found.

Take your research to the next level.
Login now to unlock Exclusive Features!

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: